Oculis Holding AG

Update in progress

OCS (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Oculis Holding AG is a clinical-stage biopharmaceutical company focused on medicines for eye, neuro-ophthalmic and neurological diseases, with activities in Switzerland and globally. Its lead program, OCS-01, is a topical dexamethasone ophthalmic formulation in Phase 3 for diabetic macular edema. OCS-02 is a topical biologic in Phase 2b for dry eye disease; OCS-05 targets neuroprotection for glaucoma, dry AMD, diabetic retinopathy and acute optic neuritis. Formerly Oculis SA, it renamed in March 2023. Founded 2017, based in Zug, Switzerland.

Company score

Sentiment: 0.45; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive